Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2086 to 2100 of 8215 results

  1. Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Cosibelimab for treating advanced cutaneous squamous cell carcinoma when curative surgery or radiotherapy is unsuitable [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date: TBC

    NICE guideline
    In development

  4. Levodopa inhaled for patients with Parkinson's disease who experience 'off' episodes (motor response fluctuations) [TSID8778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]

    Awaiting development Reference number: GID-TA11825 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10404 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  9. Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  10. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]

    In development Reference number: GID-HST10061 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  11. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

    Interventional procedures guidance
    In development

  12. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  13. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  14. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date:  04 June 2026

    Technology appraisal guidance
    In development

  15. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development